Pharmacokinetic evaluation of two oral formulations of chlorpromazine in healthy subjects

were 1.0490 (0.9534 - 1.1542) and 0.9941 (0.9261 - 1.0671), respectively, falling within the accepted bioequivalence range of 0.80 - 1.25. Among the 70 subjects who received at least 1 dose, 116 AEs were reported in 48 individuals; all were mild in intensity and resolved without sequelae, and no serious AEs occurred. These findings confirm the pharmacokinetic bioequivalence and favorable tolerability of the two formulations under fasting conditions in healthy adults and support the use of Neomazine as a therapeutically equivalent and clinically interchangeable alternative to Chlorpromazine HCl.